Barry Ticho - 03 Nov 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
03 Nov 2025
Net transactions value
-$152,566
Form type
4
Filing time
05 Nov 2025, 16:20:58 UTC
Previous filing
03 Oct 2025
Next filing
03 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ticho Barry CHIEF MEDICAL OFFICER C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 05 Nov 2025 0001780088

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Sale $95,247 -3,776 -29% $25.22 9,350 03 Nov 2025 Direct F1, F2
transaction STOK Common Stock Sale $37,860 -1,455 -16% $26.02 7,895 03 Nov 2025 Direct F1, F3
transaction STOK Common Stock Sale $16,524 -600 -7.6% $27.54 7,295 03 Nov 2025 Direct F1, F4
transaction STOK Common Stock Sale $2,935 -100 -1.4% $29.35 7,195 03 Nov 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.74 to $25.65 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 4.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.79 to $26.50 per share, inclusive.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.60 per share, inclusive.